Skip to main content

Table 2 Treatment-related adverse events

From: A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint

Event-no.(%)

Cohort 1 (N = 7)

Cohort 2 (N = 10)

All grades

Grade 3 or 4

All grades

Grade 3 or 4

Any event

7 (100)

3 (43)

10 (100)

5 (50)

Injection Site Reactions**

    

GVAX

7 (100)

0

8 (80)

0

Guadecitabine

5 (71)

0

7 (70)

0

Generalized Symptoms

    

Fatigue

5 (71)

0

8 (80)

3 (30)

Fever/Chills

3 (43)

0

2 (20)

0

Myalgia

2 (29)

0

1 (10)

0

Headache

1 (14)

0

3 (30)

0

Flu-like illness

0

0

1 (10)

0

Dizziness

1 (14)

0

0

0

Gastrointestinal

    

Constipation

2 (29)

0

2 (20)

0

Nausea/vomiting

3 (43)

0

2 (20)

0

Diarrhea

0

0

1 (10)

0

Flatulence

1 (14)

0

0

0

Hematologic

    

Neutropenia

3 (43)

3 (43)

4 (40)

4 (40)

Leukopenia

0

0

1 (10)

1 (10)

Anemia

1 (14)

0

0

0

Dermatologic

    

Rash/Pruritis

0

0

2 (20)

0

Hives

1 (14)

0

0

0

Other

    

Cough

1 (14)

0

0

0

Warmth, thighs

1 (14)

0

0

0

  1. *Events were counted once for each patient using the highest grading
  2. **Includes erythema, induration, pruritis, hyperpigmentation, tenderness